Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

Santen Oy150 enrolled

Overview

The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

150

Conditions

Ocular Hypertension Open-Angle Glaucoma

Interventions

tafluprostDRUG

prostaglandine analoque

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable patients must have ocular surface related symptoms and/or signs with their prior medication.

Locations (1)

Finn-Medi Research Oy

Tampere, Finland

Outcomes

Primary Outcomes

Change from screening in ocular symptoms and signs

Time frame: at week 6 and 12

Secondary Outcomes

Safety and Quality of life parameters.

Time frame: From Screening (visit 1) to visits at week 2, 6 and 12.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.